Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6575446 | 0.79 | CHRNB2 (0.45) | CHRNB2CHRNA4P2RY14 | |
| SCHEMBL7214949 | 0.73 | CHRNB2 (0.52) | CHRNB2CHRNA4P2RY14 | |
| Hydrochloric Acid SCHEMBL18111494 | 0.71 | CHRNB2 (0.54) | CHRNB2CHRNA4P2RY14 | |
| SCHEMBL7210041 | 0.69 | SLC6A2 (0.48) | MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL472165 | 0.69 | CA12 (0.57) | ADRA2AADRA2BADRA2CMAPTKDM4E | |
| SCHEMBL9065504 | 0.69 | CA12 (0.57) | ADRA2AADRA2BADRA2CMAPTKDM4E | |
| SCHEMBL6577750 | 0.69 | P2RY14 (0.59) | CHRNB2CHRNA4P2RY14 | |
| 1,4-Diallyloxybenzene SCHEMBL302448 | 0.67 | CA12 (0.63) | ADRA2AADRA2BADRA2CMAPTKDM4E | |
| SCHEMBL5194310 | 0.66 | CHRNB2 (0.51) | CHRNB2CHRNA4P2RY14 | |
| SCHEMBL5194296 | 0.66 | CHRNB2 (0.51) | CHRNB2CHRNA4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010047028-A1 | Novel azabicyclo derivatives and their use | ANIONA APS (DK) | 2001-11-29 | — | — | US | claimed |
| EP-1149095-A1 | NOVEL AZABICYCLO DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2001-10-31 | — | — | EP | claimed |
| WO-2000044746-A1 | NOVEL AZABICYCLO DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2000-08-03 | — | — | WO | claimed |
| US-6617459-B2 | 8-azabicyclo(3.2.1)oct-2-ene and 9-azabicyclo(3.3.1)non-2-ene derivatives; monoamine neurotransmitter and serotonine reuptake inhibitors; radionuclide-labeled derivatives for diagnosis and detection | NEUROSEARCH A/S (DK) | 2003-09-09 | — | — | US | disclosed |
| US-20010047028-A1 | Novel azabicyclo derivatives and their use | ANIONA APS (DK) | 2001-11-29 | — | — | US | disclosed |
| EP-1149095-A1 | NOVEL AZABICYCLO DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000044746-A1 | NOVEL AZABICYCLO DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047028-A1 | Novel azabicyclo derivatives and their use | TACR2, TACR3, GPR68 | CHRNB2 66/4885CHRNA4 117/4885ADRA2A 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.